Foghorn Therapeutics. has filed a patent for compounds aimed at treating BAF complex-related disorders. The claim describes a specific compound structure for potential pharmaceutical use. GlobalData’s report on Foghorn Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Foghorn Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Foghorn Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Foghorn Therapeutics's grant share as of January 2024 was 5%. Grant share is based on the ratio of number of grants to total number of patents.

A patent application (Publication Number: US20240024488A1) has been filed for a compound or a pharmaceutically acceptable salt thereof with a specific chemical structure outlined in Formula I. The compound, as described in the claims, includes various structural variations denoted by different formulas such as Formula I-A, Formula I-G, and Formula I-H. The patent also covers methods of treating BAF complex-related disorders, disorders related to BRG1 loss of function mutations, and cancer by administering the compound to the subject. The compound's effectiveness in treating various types of cancer, including non-small cell lung cancer, colorectal cancer, melanoma, and prostate cancer, is highlighted in the claims.

Furthermore, the patent application includes detailed descriptions of the compound's structure, degradation moieties, linkers, and their specific configurations. The compound's ability to target specific disorders related to genetic mutations and its potential therapeutic applications in treating a wide range of cancers are emphasized. The claims also mention the compound's specific ratio of BRG1 IC50 to BRM IC50, which is crucial for its efficacy in treating cancer. Overall, the patent application aims to protect the compound's unique structure and its potential as a treatment for various cancer types and genetic disorders, providing a comprehensive overview of its pharmaceutical applications and therapeutic benefits.

To know more about GlobalData’s detailed insights on Foghorn Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies